Now Playing
News|Videos|October 16, 2023
An Overview of PSMA-PET Scans and Prostate Cancer Imaging
Author(s)David Albala, MD
Join David Albala, MD, as he explores the use of advanced imaging techniques in prostate cancer diagnosis and management, highlighting PSMA-PET scans and their pivotal role in modern prostate cancer care.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Advertisement
Advertisement
Trending on Urology Times
1
PTEN loss: From biomarker to treatment strategy in mHSPC
2
Q&A: Gary Kirsh, MD, on health policy for independent urology
3
Modern BCG outperforms historic benchmarks in high-risk NMIBC
4
Q&A: Suzanne B. Merrill, MD, FACS, on treating high-risk NMIBC
5